Dashboard
Manage Tickers

AMGN AMGEN INC

Nasdaq amgen.com


$ 338.17 $ -6.40 (-1.86 %)    

Thursday, 20-Nov-2025 15:43:19 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 586.24 $ -25.43 (-4.16 %)
DIA $ 458.49 $ -8.17 (-1.75 %)
SPY $ 653.43 $ -19.47 (-2.89 %)
TLT $ 89.29 $ 0.30 (0.33 %)
GLD $ 374.68 $ -0.50 (-0.13 %)
$ 342.4
$ 343.47
$ 338.13 x 35
$ 338.09 x 30
$ 336.61 - $ 345.00
$ 247.06 - $ 345.84
2,129,822
na
184.38B
$ 0.44
$ 26.32
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-05-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 08-06-2024 06-30-2024 10-Q
7 05-02-2024 03-31-2024 10-Q
8 02-14-2024 12-31-2023 10-K
9 10-31-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 04-28-2023 03-31-2023 10-Q
12 02-09-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 04-28-2022 03-31-2022 10-Q
16 02-16-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 04-28-2021 03-31-2021 10-Q
20 02-09-2021 12-31-2020 10-K
21 10-29-2020 09-30-2020 10-Q
22 07-29-2020 06-30-2020 10-Q
23 05-01-2020 03-31-2020 10-Q
24 02-12-2020 12-31-2019 10-K
25 10-30-2019 09-30-2019 10-Q
26 07-31-2019 06-30-2019 10-Q
27 05-01-2019 03-31-2019 10-Q
28 02-13-2019 12-31-2018 10-K
29 10-31-2018 09-30-2018 10-Q
30 07-27-2018 06-30-2018 10-Q
31 04-25-2018 03-31-2018 10-Q
32 02-13-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-26-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-14-2017 12-31-2016 10-K
37 10-28-2016 09-30-2016 10-Q
38 07-29-2016 06-30-2016 10-Q
39 05-02-2016 03-31-2016 10-Q
40 02-16-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-signs-off-on-bayers-new-lung-cancer-drug--early-results-look-promising
FDA Signs Off On Bayer's New Lung Cancer D...
11/20/2025 17:53:24

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options f...

reported-november-19-2025-amgens-imdelltra-receives-fda-approval-for-extensive-stage-small-cell-lung-cancer-after-phase-3-trial-shows-40-reduction-in-death-risk-compared-to-chemotherapy
Reported November 19, 2025: Amgen's IMDELL...
11/20/2025 14:45:22

Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death by 40% Compared to ChemotherapyUnderscores...

Core News & Articles
FDA Grants Accelerated Approval To Sevaber...
11/19/2025 19:45:17

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-

tech-stocks-drop-pharma-gains-as-sector-rotation-picks-up-whats-moving-markets-tuesday
Tech Stocks Drop, Pharma Gains As Sector R...
11/18/2025 18:15:11

Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New Y...

Core News & Articles
Live On CNBC, Josh Brown Hosts Segment Tit...
11/18/2025 17:40:59

check-out-what-whales-are-doing-with-amgn
Check Out What Whales Are Doing With AMGN
11/18/2025 17:01:24

fear-of-an-ai-bubble-this-sector-is-quietly-surging-while-tech-sinks
Fear Of An AI Bubble? This Sector Is Quiet...
11/14/2025 20:17:19

While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.

piper-sandler-maintains-overweight-on-amgen-raises-price-target-to-381
Piper Sandler Maintains Overweight on Amge...
11/14/2025 13:50:11

Piper Sandler analyst David Amsellem maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $342 t...

a-closer-look-at-amgens-options-market-dynamics
A Closer Look at Amgen's Options Market Dy...
11/13/2025 15:02:25

amgens-repatha-cuts-risk-of-first-major-adverse-cardiovascular-events-by-25-heart-attack-risk-by-36-in-phase-3-vesalius-cv-trial
Amgen's Repatha Cuts Risk Of First Major A...
11/08/2025 15:22:27

Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (e...

watching-amgen-hearing-investor-business-daily-swingtrader-buys-stock
Watching Amgen; Hearing Investor Business ...
11/07/2025 18:57:23

cantor-fitzgerald-maintains-neutral-on-amgen-raises-price-target-to-315
Cantor Fitzgerald Maintains Neutral on Amg...
11/06/2025 15:06:36

Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $305 to...

stocks-rebound-eli-lilly-jumps-to-14-month-highs-whats-moving-markets-wednesday
Stocks Rebound, Eli Lilly Jumps To 14-Mont...
11/05/2025 18:23:55

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...

morgan-stanley-maintains-equal-weight-on-amgen-lowers-price-target-to-329
Morgan Stanley Maintains Equal-Weight on A...
11/05/2025 17:59:53

Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $333...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
11/05/2025 17:35:20

wells-fargo-maintains-overweight-on-amgen-raises-price-target-to-300
Wells Fargo Maintains Overweight on Amgen,...
11/05/2025 15:00:26

Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $280 to $300.

amgen-raises-fy2025-sales-guidance-from-35000b-36000b-to-35800b-36600b-vs-35659b-est
Amgen Raises FY2025 Sales Guidance from $3...
11/04/2025 21:36:15

2025 GuidanceFor the full year 2025, the Company expects:Total revenues in the range of $35.8 billion to $36.6 billion.On a GAA...

amgen-raises-fy2025-gaap-eps-guidance-from-1097-1211-to-1376-1460-vs-1136-est
Amgen Raises FY2025 GAAP EPS Guidance from...
11/04/2025 21:03:40

Amgen Inc.Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2025(Unaudited)       G...

amgen-raises-fy2025-adj-eps-guidance-from-2020-2130-to-2060-2140-vs-2103-est
Amgen Raises FY2025 Adj EPS Guidance from ...
11/04/2025 21:03:17

Amgen (NASDAQ:AMGN) raises FY2025 Adj EPS guidance from $20.20-$21.30 to $20.60-$21.40 vs $21.03 analyst estimate..

amgen-q3-adj-eps-564-beats-501-estimate-sales-9557b-beat-8967b-estimate
Amgen Q3 Adj. EPS $5.64 Beats $5.01 Estima...
11/04/2025 21:02:20

Amgen (NASDAQ:AMGN) reported quarterly earnings of $5.64 per share which beat the analyst consensus estimate of $5.01 by 12.49 ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION